CASI Pharmaceuticals (CASIF) Non Operating Income (2022 - 2025)

CASI Pharmaceuticals has reported Non Operating Income for 4 years, with the latest figure at $12000.0 in Q2 2025.

• For the quarter ending Q2 2025, Non Operating Income fell 33.33% year-over-year to $12000.0; the trailing twelve-month figure through Jun 2025 stood at $206000.0 (up 109.85% YoY), and the FY2025 full-year result was $20000.0, down 89.36% from the prior year.
• Non Operating Income for Q2 2025 stood at $12000.0, down from $18000.0 in the prior quarter.
• The five-year high for Non Operating Income was $1.3 million in Q1 2023, with the low at -$2.7 million in Q4 2023.
• Historically, Non Operating Income has averaged -$55916.7 across 4 years, with a median of $15000.0 in 2024.
• The largest YoY upside for Non Operating Income was 4200.0% in 2023 against a maximum downside of 17025.0% in 2023.
• CASI Pharmaceuticals' Non Operating Income stood at -$16000.0 in 2022, then sank by 17025.0% to -$2.7 million in 2023, then jumped by 100.66% to $18000.0 in 2024, then plunged by 33.33% to $12000.0 in 2025.
• The last three Non Operating Income figures came in at $12000.0 (Q2 2025), $18000.0 (Q1 2025), and $18000.0 (Q2 2024), per Business Quant data.